Physician profile
Thierry P Bonnabesse
NPI 1487749974
$20,861.01
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,477 · 2020: $420 · 2021: $464 · 2022: $1,010 · 2023: $2,708 · 2024: $2,453 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Food and Beverage: $7,052 · Travel and Lodging: $1,562 · Consulting Fee: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Food and Beverage | $7,052.35 |
| Travel and Lodging | $1,561.79 |
| Consulting Fee | $675.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,951.21 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Mml US, INC. | $1,931.70 | 2022-2025 | Reactiv8 |
| Vertiflex, INC. | $1,580.56 | 2019 | |
| Relievant Medsystems, INC. | $1,308.77 | 2021-2023 | Intracept |
| Saluda Medical Americas, INC. | $501.60 | 2023-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $192.06 | 2019-2024 | Proclaim |
| Vertos Medical, INC. | $185.00 | 2021-2024 | Mild Device Kit |
| Nalu Medical, INC. | $160.34 | 2021-2023 | Nalu Neurostimulation System |
| Stryker Corporation | $152.42 | 2020-2025 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $122.16 | 2020-2024 | Xtampza |
| Si-Bone, INC. | $118.61 | 2022-2025 | |
| Medtronic, INC. | $76.23 | 2024 | Inceptiv |
| Curonix LLC | $76.23 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $68.55 | 2019 | |
| Spr Therapeutics, INC | $66.14 | 2024-2025 | Sprint Pns System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $63.44 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $42.08 | 2019-2020 | |
| Medtronic USA, INC. | $36.11 | 2019-2020 | |
| Pfizer INC. | $32.27 | 2020-2021 | |
| Medtronic Vascular, INC. | $27.63 | 2019 | |
| Lundbeck LLC | $27.39 | 2023 | Vyepti |
| Ipsen Biopharmaceuticals, INC | $26.42 | 2024 | Dysport |
| Abbvie INC. | $26.39 | 2024 | |
| Pacira Therapeutics, INC. | $21.66 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.96 | 2023 | Ztlido |
| Amgen INC. | $16.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.60 | 2019 | |
| Fidia Pharma USA INC. | $14.03 | 2023 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thierry Bonnabesse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.